Nuance Investments LLC Sells 2,544,320 Shares of Envista Holdings Co. (NYSE:NVST)

Nuance Investments LLC cut its stake in Envista Holdings Co. (NYSE:NVST) by 34.6% in the 4th quarter, Holdings Channel.com reports. The fund owned 4,802,214 shares of the company’s stock after selling 2,544,320 shares during the quarter. Envista comprises approximately 3.7% of Nuance Investments LLC’s investment portfolio, making the stock its 8th biggest position. Nuance Investments LLC’s holdings in Envista were worth $92,635,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of NVST. Franklin Resources Inc. raised its stake in Envista by 26.5% in the third quarter. Franklin Resources Inc. now owns 3,971,662 shares of the company’s stock valued at $78,480,000 after purchasing an additional 830,861 shares in the last quarter. Geode Capital Management LLC increased its holdings in Envista by 2.5% in the 3rd quarter. Geode Capital Management LLC now owns 2,895,653 shares of the company’s stock valued at $57,233,000 after buying an additional 71,435 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of Envista by 8.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,317,631 shares of the company’s stock valued at $44,707,000 after buying an additional 179,600 shares in the last quarter. Iron Triangle Partners LP bought a new stake in shares of Envista during the 3rd quarter worth approximately $43,262,000. Finally, Point72 Asset Management L.P. acquired a new stake in shares of Envista during the 3rd quarter worth approximately $37,559,000.

Analysts Set New Price Targets

NVST has been the subject of several recent analyst reports. Mizuho started coverage on Envista in a research note on Wednesday, December 4th. They set an “underperform” rating and a $20.00 target price for the company. Wells Fargo & Company set a $19.00 price objective on Envista in a research note on Saturday, March 8th. UBS Group lowered their target price on Envista from $23.00 to $21.00 and set a “neutral” rating for the company in a research note on Monday, March 10th. Morgan Stanley reduced their price target on shares of Envista from $20.00 to $19.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 6th. Finally, Piper Sandler increased their price objective on shares of Envista from $17.00 to $18.00 and gave the company a “neutral” rating in a research note on Monday, February 3rd. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, Envista presently has a consensus rating of “Hold” and a consensus price target of $20.18.

Envista Trading Down 0.2 %

NYSE:NVST opened at $17.44 on Wednesday. Envista Holdings Co. has a 52 week low of $15.15 and a 52 week high of $23.00. The firm’s fifty day moving average is $19.70 and its 200-day moving average is $19.61. The firm has a market cap of $3.00 billion, a P/E ratio of -2.69, a P/E/G ratio of 1.27 and a beta of 1.33. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.76 and a current ratio of 2.04.

Envista (NYSE:NVST) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. Equities analysts expect that Envista Holdings Co. will post 1 earnings per share for the current year.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.